Our clinical and mechanistic findings establish that the Arl4c-Yap-CTGF axis is critical for pancreatic cancer progression and that treatments targeting this axis might be a potential therapeutic strategy for pancreatic cancer. The gene discussed is ARL4C; the disease is familial pancreatic carcinoma.